Pub Date : 2008-11-01DOI: 10.1097/01.IDT.0000338579.72194.97
M. A. Webber, Joan M. Farrell
neous and markedly impairing syndrome that often is associated with multiple comorbid psychiatric disorders. Accordingly, these patients require multifaceted care from trained mental health professionals. The need is substantial. Recent findings from the extensive Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions suggest a prevalence rate of 5.9% in the general population, which is higher than the previous estimates of 1%–2%. Notably, this study documented no significant difference in prevalence rates between males and females.
{"title":"Pharmacotherapy of Borderline Personality Disorder","authors":"M. A. Webber, Joan M. Farrell","doi":"10.1097/01.IDT.0000338579.72194.97","DOIUrl":"https://doi.org/10.1097/01.IDT.0000338579.72194.97","url":null,"abstract":"neous and markedly impairing syndrome that often is associated with multiple comorbid psychiatric disorders. Accordingly, these patients require multifaceted care from trained mental health professionals. The need is substantial. Recent findings from the extensive Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions suggest a prevalence rate of 5.9% in the general population, which is higher than the previous estimates of 1%–2%. Notably, this study documented no significant difference in prevalence rates between males and females.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000338579.72194.97","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-09-01DOI: 10.1097/01.IDT.0000334723.91820.15
J. Grant, M. Potenza
toward rapid, unplanned reactions to either internal or external stimuli with diminished regard for negative consequences. Given this definition, multiple psychiatric disorders might be characterized as exhibiting problems with impulse control. In the fourth edition of the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV-TR), the category “impulse control disorders not elsewhere classified” includes pathologic gambling (PG), trichotillomania, intermittent explosive disorder (IED), kleptomania, and pyromania. Despite high prevalence rates in the general population, impulse control disorders have been relatively understudied. The disorder that arguably has been the best researched (i.e., PG) has been systematically investigated only recently with respect to empirically supported pharmacologic treatments. Because rigorous research is particularly limited for pyromania, this article will review the available research on the treatment of PG, trichotillomania, IED, and kleptomania. PATHOLOGIC GAMBLING PG is characterized by persistent and recurrent maladaptive patterns of gambling behavior and is associated with impaired functioning, reduced quality of life, decreased work productivity, and high rates of bankruptcy and relationship problems. PG usually begins in adolescence or early adulthood, with males tending to start at an earlier age. In epidemiologic studies, women represent approximately 32% After reading this article, the practitioner should be able to:
{"title":"Pharmacologic Treatment of Impulse Control Disorders","authors":"J. Grant, M. Potenza","doi":"10.1097/01.IDT.0000334723.91820.15","DOIUrl":"https://doi.org/10.1097/01.IDT.0000334723.91820.15","url":null,"abstract":"toward rapid, unplanned reactions to either internal or external stimuli with diminished regard for negative consequences. Given this definition, multiple psychiatric disorders might be characterized as exhibiting problems with impulse control. In the fourth edition of the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV-TR), the category “impulse control disorders not elsewhere classified” includes pathologic gambling (PG), trichotillomania, intermittent explosive disorder (IED), kleptomania, and pyromania. Despite high prevalence rates in the general population, impulse control disorders have been relatively understudied. The disorder that arguably has been the best researched (i.e., PG) has been systematically investigated only recently with respect to empirically supported pharmacologic treatments. Because rigorous research is particularly limited for pyromania, this article will review the available research on the treatment of PG, trichotillomania, IED, and kleptomania. PATHOLOGIC GAMBLING PG is characterized by persistent and recurrent maladaptive patterns of gambling behavior and is associated with impaired functioning, reduced quality of life, decreased work productivity, and high rates of bankruptcy and relationship problems. PG usually begins in adolescence or early adulthood, with males tending to start at an earlier age. In epidemiologic studies, women represent approximately 32% After reading this article, the practitioner should be able to:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000334723.91820.15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-08-01DOI: 10.1097/01.IDT.0000330316.55872.6B
Pamela Vergara-Rodriguez, J. Watts
anxiety disorders (Tables 1–3). Our focus in Part II is schizophrenia, sleep disorders, and pain syndromes. In addition, we review the 2008 HIV Treatment Guidelines Update for patients with no previous exposure to HIV antiretrovirals, as well as the newly approved HIV medications (raltegravir, etravirine, and maraviroc) as they relate to HIV patients treated for comorbid psychiatric disorders. Importantly, these new medications are approved for treatment-experienced patients (previous exposure to HIV antiretrovirals) with known antiretroviral resistance, and require antiretroviral resistance testing and follow-up with an HIV specialist. In this article, we describe recommended practices for the use of psychotropic medications in patients receiving highly active antiretroviral therapy (HAART). For most patients, HAART is a triple antiretroviral combination including two nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) and either a non-nucleoside/non-nucleotide reverse transcriptase inhibitor (NNRTI) or a ritonavirboosted protease inhibitor (PI). Commonly used agents are listed in Table 1. However, for treatment-experienced patients with HIV who have developed resistance to one or more classes of antiretroviral agents, HAART may use a combination of NRTIs, NNRTIs, and PIs as well as the new classes of HIV drugs discussed in this article.
{"title":"Use of Psychotropic Medications in the HIV‐Positive Patient: Part I","authors":"Pamela Vergara-Rodriguez, J. Watts","doi":"10.1097/01.IDT.0000330316.55872.6B","DOIUrl":"https://doi.org/10.1097/01.IDT.0000330316.55872.6B","url":null,"abstract":"anxiety disorders (Tables 1–3). Our focus in Part II is schizophrenia, sleep disorders, and pain syndromes. In addition, we review the 2008 HIV Treatment Guidelines Update for patients with no previous exposure to HIV antiretrovirals, as well as the newly approved HIV medications (raltegravir, etravirine, and maraviroc) as they relate to HIV patients treated for comorbid psychiatric disorders. Importantly, these new medications are approved for treatment-experienced patients (previous exposure to HIV antiretrovirals) with known antiretroviral resistance, and require antiretroviral resistance testing and follow-up with an HIV specialist. In this article, we describe recommended practices for the use of psychotropic medications in patients receiving highly active antiretroviral therapy (HAART). For most patients, HAART is a triple antiretroviral combination including two nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) and either a non-nucleoside/non-nucleotide reverse transcriptase inhibitor (NNRTI) or a ritonavirboosted protease inhibitor (PI). Commonly used agents are listed in Table 1. However, for treatment-experienced patients with HIV who have developed resistance to one or more classes of antiretroviral agents, HAART may use a combination of NRTIs, NNRTIs, and PIs as well as the new classes of HIV drugs discussed in this article.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000330316.55872.6B","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-07-01DOI: 10.1097/01.IDT.0000325061.73022.3c
S. Dowd, P. Janicak
Dr. Dowd has disclosed that she was the recipient of grant/research support from Astra-Zeneca and Bristol-Meyers Squibb; was/is the recipient of grant/research support from Janssen, Neuronetics, sanofi-aventis, and Solvay; and is a consultant/advisor to Neuronetics. Dr. Janicak has disclosed that he was the recipient of grant research support from Astra-Zeneca and Bristol-Meyers Squibb; is/was the recipient of grant research support from Janssen, Neuronetics, sanofi-aventis, and Solvay; was/is a consultant/advisor to Astra-Zeneca, BristolMeyers Squibb, Janssen, Neuronetics, and Solvay; and is/was a member of the speakers bureau for Abbott, Astra-Zeneca, Bristol-Meyers Squibb, and Pfizer.
{"title":"An Update on Diagnostic and Treatment Issues in the Management of Post‐Traumatic Stress Disorder","authors":"S. Dowd, P. Janicak","doi":"10.1097/01.IDT.0000325061.73022.3c","DOIUrl":"https://doi.org/10.1097/01.IDT.0000325061.73022.3c","url":null,"abstract":"Dr. Dowd has disclosed that she was the recipient of grant/research support from Astra-Zeneca and Bristol-Meyers Squibb; was/is the recipient of grant/research support from Janssen, Neuronetics, sanofi-aventis, and Solvay; and is a consultant/advisor to Neuronetics. Dr. Janicak has disclosed that he was the recipient of grant research support from Astra-Zeneca and Bristol-Meyers Squibb; is/was the recipient of grant research support from Janssen, Neuronetics, sanofi-aventis, and Solvay; was/is a consultant/advisor to Astra-Zeneca, BristolMeyers Squibb, Janssen, Neuronetics, and Solvay; and is/was a member of the speakers bureau for Abbott, Astra-Zeneca, Bristol-Meyers Squibb, and Pfizer.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000325061.73022.3c","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1097/01.IDT.0000320300.64558.ff
E. Scott, K. Walsh, C. McDougle
den, rapid, involuntary, stereotypical but nonrhythmic movements and vocalizations. Common motor tics include eye blinking, lip lifting, nose wrinkling, and shoulder shrugging. Common vocal tics may include sniffing, grunting, throat clearing, and chirping. According to the DSM-IV-TR, multiple motor or vocal tics must be present at some time during the illness, though not necessarily concurrently. The tics usually occur multiple times per day, nearly every day for at least 1 year, although there can be tic-free periods lasting up to 3 months. TS should be distinguished from other movement disorders (e.g., stereotypies, Huntington chorea, Sydenham chorea, epilepsy, myoclonus, spasmodic torticollis, postviral encephalitis). The prevalence of TS among 13and 14-year-olds varies widely, with estimates ranging from 31–157/1000 children in European and Asian samples. In contrast, the prevalence of simple tics in the general population ranges from 6%–20% of all children. To be diagnosed with TS, patients must have tic onset before age 18. Developmentally, most simple motor tics begin after the age of 3 and reach their peak around age 5. Children who go on to develop TS will have their motor tics continue through age 5 with frequency peaking between ages 9 and 12, typically subsiding thereafter. Vocal tics tend to have a later onset, usually occurring by age 11. Researchers agree that the severity of TS in most individuals begins to wane during the early 20s. Patients with persistent TS will experience a waxing and waning pattern of After reading this article, the practitioner should be able to:
{"title":"Treatment of Tourette's Syndrome","authors":"E. Scott, K. Walsh, C. McDougle","doi":"10.1097/01.IDT.0000320300.64558.ff","DOIUrl":"https://doi.org/10.1097/01.IDT.0000320300.64558.ff","url":null,"abstract":"den, rapid, involuntary, stereotypical but nonrhythmic movements and vocalizations. Common motor tics include eye blinking, lip lifting, nose wrinkling, and shoulder shrugging. Common vocal tics may include sniffing, grunting, throat clearing, and chirping. According to the DSM-IV-TR, multiple motor or vocal tics must be present at some time during the illness, though not necessarily concurrently. The tics usually occur multiple times per day, nearly every day for at least 1 year, although there can be tic-free periods lasting up to 3 months. TS should be distinguished from other movement disorders (e.g., stereotypies, Huntington chorea, Sydenham chorea, epilepsy, myoclonus, spasmodic torticollis, postviral encephalitis). The prevalence of TS among 13and 14-year-olds varies widely, with estimates ranging from 31–157/1000 children in European and Asian samples. In contrast, the prevalence of simple tics in the general population ranges from 6%–20% of all children. To be diagnosed with TS, patients must have tic onset before age 18. Developmentally, most simple motor tics begin after the age of 3 and reach their peak around age 5. Children who go on to develop TS will have their motor tics continue through age 5 with frequency peaking between ages 9 and 12, typically subsiding thereafter. Vocal tics tend to have a later onset, usually occurring by age 11. Researchers agree that the severity of TS in most individuals begins to wane during the early 20s. Patients with persistent TS will experience a waxing and waning pattern of After reading this article, the practitioner should be able to:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000320300.64558.ff","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-05-01DOI: 10.1097/01.IDT.0000316718.89905.30
K. Pierce, Patricia Flynn, Marty Caudle, Keith S. Garcia
symptoms have existed since the early 1900s. They were developed in response to the observation that patients who suffered from endogenous seizures demonstrated relief from psychiatric symptoms. Although most of these methods were abandoned because of high rates of morbidity and mortality, the use of electrically induced controlled seizure activity to treat psychiatric disorders continued to attract attention. Over the years, ongoing refinements in the method of administrating electroconvulsive therapy (ECT) have included: • Optimization of the dosing and localization of electrical charge; • Use of anesthesia; and • Psychiatric and medical screening of patients to assess their appropriateness for treatment and to anticipate potential adverse events. As a result, ECT has become one of the safest and most broadly effective treatments, particularly for major depressive disorder (MDD). We discuss the indications for ECT, describe its administration, outline its important side effects and issues related to screening for medical risk, and review recent advances.
{"title":"Electroconvulsive Therapy: Current Clinical Standards","authors":"K. Pierce, Patricia Flynn, Marty Caudle, Keith S. Garcia","doi":"10.1097/01.IDT.0000316718.89905.30","DOIUrl":"https://doi.org/10.1097/01.IDT.0000316718.89905.30","url":null,"abstract":"symptoms have existed since the early 1900s. They were developed in response to the observation that patients who suffered from endogenous seizures demonstrated relief from psychiatric symptoms. Although most of these methods were abandoned because of high rates of morbidity and mortality, the use of electrically induced controlled seizure activity to treat psychiatric disorders continued to attract attention. Over the years, ongoing refinements in the method of administrating electroconvulsive therapy (ECT) have included: • Optimization of the dosing and localization of electrical charge; • Use of anesthesia; and • Psychiatric and medical screening of patients to assess their appropriateness for treatment and to anticipate potential adverse events. As a result, ECT has become one of the safest and most broadly effective treatments, particularly for major depressive disorder (MDD). We discuss the indications for ECT, describe its administration, outline its important side effects and issues related to screening for medical risk, and review recent advances.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000316718.89905.30","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-04-01DOI: 10.1097/01.IDT.0000314887.61319.fa
K. Walsh, E. Scott, C. McDougle
O bsessive-compulsive disorder (OCD) is a common anxiety disorder, affecting 1% to 3% of the population. Patients struggle with obsessive thoughts, compulsive rituals, and avoidance behaviors. Symptoms are time-consuming, intrusive, and difficult to resist. The disorder is chronic, tends to wax and wane in severity over a patient’s lifetime, and rarely remits spontaneously. Suicide attempts have been reported by 10% to 27% of patients with OCD and are particularly likely in those with more severe illness or depressive comorbidity. The use of serotonin reuptake inhibitors (SRIs) and cognitive-behavioral therapy (CBT) with exposure and ritual prevention (E/RP) revolutionized the care of this previously untreatable illness. The Expert Consensus Panel for OCD has recommended CBT alone as first-line treatment for milder OCD in adults and an SRIwith or without CBT for more severe OCD. Proper implementation of these interventions, however, requires patience and expertise. Response to SRIs in treatment of OCD is slower than that seen in treatment of depression. For instance, in one clomipramine trial, maximum symptom reduction did not occur until the 10th week of treatment. Because OCD symptoms respond more slowly to SRI treatment, an adequate trial would be 8 to 12 After reading this article, the practitioner should be able to:
{"title":"The Use of Antipsychotics in the Treatment of Obsessive‐Compulsive Disorder","authors":"K. Walsh, E. Scott, C. McDougle","doi":"10.1097/01.IDT.0000314887.61319.fa","DOIUrl":"https://doi.org/10.1097/01.IDT.0000314887.61319.fa","url":null,"abstract":"O bsessive-compulsive disorder (OCD) is a common anxiety disorder, affecting 1% to 3% of the population. Patients struggle with obsessive thoughts, compulsive rituals, and avoidance behaviors. Symptoms are time-consuming, intrusive, and difficult to resist. The disorder is chronic, tends to wax and wane in severity over a patient’s lifetime, and rarely remits spontaneously. Suicide attempts have been reported by 10% to 27% of patients with OCD and are particularly likely in those with more severe illness or depressive comorbidity. The use of serotonin reuptake inhibitors (SRIs) and cognitive-behavioral therapy (CBT) with exposure and ritual prevention (E/RP) revolutionized the care of this previously untreatable illness. The Expert Consensus Panel for OCD has recommended CBT alone as first-line treatment for milder OCD in adults and an SRIwith or without CBT for more severe OCD. Proper implementation of these interventions, however, requires patience and expertise. Response to SRIs in treatment of OCD is slower than that seen in treatment of depression. For instance, in one clomipramine trial, maximum symptom reduction did not occur until the 10th week of treatment. Because OCD symptoms respond more slowly to SRI treatment, an adequate trial would be 8 to 12 After reading this article, the practitioner should be able to:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000314887.61319.fa","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-03-01DOI: 10.1097/01.IDT.0000311517.65367.cf
D. Osser
Learning Objectives After reading this article, the practitioner should be able to:Describe the likelihood that industry-sponsored continuing medical education will contain biases, both obvious and subtle.Recall the extent to which academic psychopharmacology is “owned” yb pharmaceutical companies.Explain the importance of joining a psychopharmacology journal club and increasing the practitioner's skills in reading the literature.
{"title":"Cleaning Up Evidence‐Based Psychopharmacology","authors":"D. Osser","doi":"10.1097/01.IDT.0000311517.65367.cf","DOIUrl":"https://doi.org/10.1097/01.IDT.0000311517.65367.cf","url":null,"abstract":"Learning Objectives After reading this article, the practitioner should be able to:Describe the likelihood that industry-sponsored continuing medical education will contain biases, both obvious and subtle.Recall the extent to which academic psychopharmacology is “owned” yb pharmaceutical companies.Explain the importance of joining a psychopharmacology journal club and increasing the practitioner's skills in reading the literature.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000311517.65367.cf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-02-01DOI: 10.1097/01.IDT.0000310564.87858.f7
J. Bishop, M. Pavuluri
done has been used clinically since its original approval in December 1993 for the treatment of schizophrenia. On August 22, 2007, it also became the first SGA to receive approval from the FDA for the treatment of schizophrenia in adolescents ages 13–17 and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10–17. This makes it the first SGA approved for these populations. In addition, it is indicated for bipolar mania and schizophrenia in adults, as well as for irritability associated with autism in children and adolescents 5–16 years of age. Risperidone is prescribed in the United States as a first-line treatment for adults and children with schizophrenia and bipolar disorders. As with most medications that serve as treatment options for children with major mental illnesses, clinicians must carefully weigh the risks and benefits. To help guide them, this review summarizes the efficacy, effectiveness, and safety data for risperidone in children and adolescents with schizophrenia or bipolar disorder. The review used the publication databases of PubMed, EMBASE, and Psych Abstracts, and publicly available clinical trial information from the FDA Center for Drug Evaluation and Research (CDER). The terms of search included “risperidone,” “risperidone and adolescent,” “risperidone and pediatric,” “risperidone and bipolar,” and “risperidone and schizophrenia” for studies of children and adolescents with bipolar disorder or schizophrenia.
{"title":"Update on the Use of Risperidone for the Treatment Of Youth With Schizophrenia and ipolar Disorder","authors":"J. Bishop, M. Pavuluri","doi":"10.1097/01.IDT.0000310564.87858.f7","DOIUrl":"https://doi.org/10.1097/01.IDT.0000310564.87858.f7","url":null,"abstract":"done has been used clinically since its original approval in December 1993 for the treatment of schizophrenia. On August 22, 2007, it also became the first SGA to receive approval from the FDA for the treatment of schizophrenia in adolescents ages 13–17 and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10–17. This makes it the first SGA approved for these populations. In addition, it is indicated for bipolar mania and schizophrenia in adults, as well as for irritability associated with autism in children and adolescents 5–16 years of age. Risperidone is prescribed in the United States as a first-line treatment for adults and children with schizophrenia and bipolar disorders. As with most medications that serve as treatment options for children with major mental illnesses, clinicians must carefully weigh the risks and benefits. To help guide them, this review summarizes the efficacy, effectiveness, and safety data for risperidone in children and adolescents with schizophrenia or bipolar disorder. The review used the publication databases of PubMed, EMBASE, and Psych Abstracts, and publicly available clinical trial information from the FDA Center for Drug Evaluation and Research (CDER). The terms of search included “risperidone,” “risperidone and adolescent,” “risperidone and pediatric,” “risperidone and bipolar,” and “risperidone and schizophrenia” for studies of children and adolescents with bipolar disorder or schizophrenia.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000310564.87858.f7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-01-01DOI: 10.1097/01.IDT.0000302884.58706.b5
D. Renshaw
Learning Objectives After reading this article, the practitioner should be able to:Describe the history of the search for effective aphrodisiacs.State the ability of various agents to impair sexual functioning.Discuss the clinical and research support for the myriad of putative aphrodisiacs, their side effects, and their potential interactions with prescribed medications.
{"title":"The Search for Aphrodisiacs","authors":"D. Renshaw","doi":"10.1097/01.IDT.0000302884.58706.b5","DOIUrl":"https://doi.org/10.1097/01.IDT.0000302884.58706.b5","url":null,"abstract":"Learning Objectives After reading this article, the practitioner should be able to:Describe the history of the search for effective aphrodisiacs.State the ability of various agents to impair sexual functioning.Discuss the clinical and research support for the myriad of putative aphrodisiacs, their side effects, and their potential interactions with prescribed medications.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000302884.58706.b5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61611866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：